Radiopharmaceuticals and Radiochemicals
for research and clinical use
We are a leading provider of PET-radiopharmaceuticals and radionuclides for the nuclear medicine community. Our expert team ensures operational safety of the cyclotrons and the highest possible product quality. Total annual output is about 35,000 patient doses. More...
Clinical dilemma in a breast cancer patient solved with PET imaging of 89Zr-trastuzumab
26/4/2012: A recent clinical case study reports the use of PET with 89Zr-trastuzumab to assess the HER2 status in a metastatic breast cancer patient. Not only did the procedure allow for accurate diagnosis, but also contributed to establish the most adequate subsequent treatment.
New 89Zr-labeled radiotracer provides clear evidence of the unique virtues of imaging with biomarkers in prostate cancer
8/4/2012: Researchers from the Memorial Sloan-Kettering Cancer Center, in New York (USA), have newly published the results of their work aiming at the development of a novel imaging tool to assess staging and treatment response in cancer. These results represent a valuable insight for the development of new radiotracers, by providing clear evidence of their unique advantages.
89Zr-radiolabeled TRC105, a chimeric monoclonal antibody binding CD105 (endoglin), successfully enables PET and Near-Infrared Fluorescence Imaging (NIRF) of 4T1 breast tumors
29/3/2012: In an effort to develop a non-invasive technique for evaluation of CD105 expression, as opposed to the standard clinical procedure of microvessel density assessment in biopsied, paraffin-embedded tumor specimens, a research group has newly published the successful results of their endeavor, using radiolabeling with 89Zr and imaging with positron emission tomography (PET).
Successful tumor dosimetry with quantitative iodine-124-PET/CT highly promising as pre-therapy for iodine-131 treatment of neuroblastoma in humans
15/3/2012: Using xenograft models of neuroblastoma in mice, researchers employed microPET/CT imaging with 124I-mIBG to estimate the radiation dose of 131I-mIBG expected to be used in tumor therapy. The promising results indicate this method as a highly promising pre-therapy tool in preparation for 131I treatment of neuroblastoma in human patients, preventing unnecessary exposure to excessive radiation.
89Zr-labeled monoclonal antibody panitumumab used in PET and MRI to assess the status of growth factor receptor HER1 in distant metastases of colorectal cancer
2/3/2012: A recent study, carried out by T. Nayak and colleagues, from the National Cancer Institute (NIH, Bethesda, Maryland, USA), reports the utility of PET and MRI with 89Zr-radiolabeled panitumumab in the assessment of HER1 status at distant metastases, in patients with colorectal cancer. In the clinical setting, these applications shall be an invaluable contribution to patient stratification, as well as in individual immunotherapy approach decisions.
News in cancer treatment: application of 89Zr-labeled nanobodies shows potential for therapy and PET imaging of HGF expressing tumors
29/2/2012: A group from the Head and Neck Surgery of the VU University Medical Center (Netherlands), together with the biopharmaceutical company Ablynx (Belgium), has successfully developed a molecular method for cancer treatment based on the use of nanobodies and their potential for Hepatocyte Growth Factor (HGF) assessment by PET imaging.
Radiolabeling of ibritumomab tiuxetan with 89Zr used to monitor the biodistribution of 90Y-ibritumomab tiuxetan (Zevalin) in radioimmunotherapy
27/2/2012: A research group from the Department of Nuclear Medicine and PET Research of the VU University Medical Center (Netherlands) has recently reported the use of 89Zr to monitor the biodistribution of 90Y-radiolabeled ibritumomab tiuxetan (Zevalin), for the first time in humans. Their study shows that 89Zr-ibritumomab tiuxetan PET scout scans may contribute in both economic and health aspects to improve radioimmunotherapy in patients with non-Hodgkin’s lymphoma.
Reviewing the current status of Iodine-124 in use in the clinical scene
9/2/2012: Imaging with positron emission tomography (PET) has been steadily finding new applications in medical fields, especially in oncology. In this context, the radionuclide iodine-124, with a half-life comparatively longer than that of many currently used radionuclides, in addition to its well-described radiochemistry, appears as a suitable candidate in the investigation of slow and intricate pharmacokinetic processes in clinical nuclear medicine, as well as in PET imaging studies of small animals.
PET with [18F]NaF produces better results than [18F]FDG in the assessment of valvular calcification and inflammation in aortic stenosis
30/1/2012: In this interesting study, the authors report the innovative use of positron emission tomography (PET) with [18F]NaF to determine to what extent calcification and inflammation contribute to the development of aortic stenosis, a heart disease with largely unknown pathophysiology.
New study contributes to the development of (radio)labeled mAb conjugates for photoimmunodetection in cancer
16/1/2012: Study was carried out to determine the amount of dye groups that can be coupled to a 89Zr-labeled mAbs, without disturbance of the conjugate’s biodistribution. Results may be a valuable contribution to the development of new mAb conugates for photoimmunodetection in cancer.
VU University Medical Center installs Philips PET/MR system
10/1/2012: Royal Philips Electronics and the VU University Medical Center, Amsterdam, have signed an agreement to install one of Philips’ Ingenuity TF PET/MR (Time-of-Flight Positron Emission Tomography/Magnetic Resonance) scanners at the centre.